

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,225
				Filing Date	February 14, 2002
				First Named Inventor	Fernando DONATE et al.
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	1	of	2	Attorney Docket Number	38342-178463

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
DB	BA	WO 02/076486	03/10/2002	Innoventus Project AB		
DB	BB	WO 94/28418	08/12/1994	Baylor College of Medicine		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
DB	CA	Morgan, et al., <i>Histidine-Rich Glycoprotein</i> , Wiley Encyclopedia of Molecular Medicine; Vol. 3., 2002, pp. 1644-1646		
	CB	Umov, et al., <i>Histone Acetyltransferase</i> , Wiley Encyclopedia of Molecular Medicine, Vol. 3, p. 2002, p. 1647		
	CC	Simantov, et al., <i>Histidine-rich Glycoprotein Inhibits the Antiangiogenic Effect of Thrombospondin-1</i> , The Journal of Clinical Investigation, January 2001, Vol. 107, No. 1, pp. 45-52		
	CD	Sabbatini, et al., <i>Presence in Human Skeletal Muscle of an AMP Deaminase-associated Protein That Reacts with an Antibody to Human Plasma Histidine-Proline-rich Glycoprotein</i> , The Journal of Histochemistry & Cytochemistry, 1999, Vol. 47, pp. 255-260		
	CE	Borza et al., <i>Histidine-Proline-rich Glycoprotein as a Plasma pH Sensor</i> , The Journal of Biological Chemistry, Vol. 273, No. 10, March 6, 1998, pp. 5493-5499		
	CF	Borza et al., <i>Acceleration of Plasminogen Activation by Tissue Plasminogen Activator on Surface-bound Histidine-proline-rich Glycoprotein</i> , The Journal of Biological Chemistry, Vol. 272, No. 8, February 28, 1997, pp. 5718-5726		
	CG	Borza et al., <i>Domain Structure and Conformation of Histidine-Proline-Rich Glycoprotein</i> , Biochemistry, 1996, pp. 1925-1934		
	CH	Brown, et al., <i>Histidine-Rich Glycoprotein and Platelet Factor 4 Mask Heparan Sulfate Proteoglycans Recognized by Acidic and Basic Fibroblast Growth Factor</i> , Biochemistry, 33, 1994, pp. 13918-13927		
DB	CI	Hutchens, et al, <i>Synthetic Metal-Binding Protein Surface Domains for Metal Ion-Dependent Interaction Chromatography I. Analysis of Bound Metal Ions by Matrix-Assisted UV Laser Desorption Time-of-flight Mass Spectrometry</i> , Journal of Chromatography, 1992 - Abstract		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/074,225
				Filing Date	February 14, 2002
				First Named Inventor	Fernando DONATE et al.
				Art Unit	1642
				Examiner Name	David J. Blanchard
Sheet	2	of	2	Attorney Docket Number	38342-178463

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP. 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JB	CK	Katagiri, et al., <i>Interaction of Heme with a Synthetic Peptide Mimicking the Putative Heme-Binding Site of Histidine-Rich Glycoprotein</i> , Biochemical and Biophysical Research Communications, 1987 - Abstract	
JB	CL	Kingston, et al., <i>Primary Structure of a Histidine-rich Proteolytic Fragment of Human Ceruloplasmin</i> , The Journal of Biological Chemistry, 1980, Vol. 225, pp. 2878-2885	
JB	CM	<i>Anti-histidine-Rich Glyco:Protein Monoclonal Antibody Used in the Determination of Histidine-Rich-Glyco-Proteins in Body Samples</i> , 1980 - Abstract	
JB	CN	Oh-Ishi, et al., <i>Possible Physiological Role of New Peptide Fragments Released from Bovine High Molecular Weight Kininogen by Plasma Kallikrein</i> , Biochemical Pharmacology, 1977, Vol. 26, pp. 115-120	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>David J. Blanchard</i>	Date Considered	11/12/04
-----------------------	---------------------------	--------------------	----------

DC:50297617.1

PATENT



FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 1 of 1

In the application of:

Fernando DONATE et al.
U.S. Application Serial No.: Unassigned
Filing Date: February 14, 2002

Examiner: Unassigned
Group Art Unit: 1636

For: HISTIDINE PROLINE RICH GLYCOPROTEIN
(HPTG) AS AN ANTI-ANGIOGENIC AND
ANTI-TUMOR AGENT

U.S. PATENT DOCUMENTS

<u>Ref #</u>	<u>Examiner's Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Name</u>	<u>(If appropriate) Filing Date</u>
--------------	--------------------------------	----------------------------	-------------	-------------	---

FOREIGN PATENT DOCUMENTS

<u>Ref #</u>	<u>Examiner's Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>If appropriate) Filing Date</u>
--------------	--------------------------------	----------------------------	-------------	----------------	--

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

<u>Ref #</u>	<u>Examiner's Initials</u>
--------------	--------------------------------

- | | | |
|----|----|---|
| 1. | DB | Brown K.J. et al., "Histidine-Rich Glycoprotein And Platelet Factor 4 Mask Heparan Sulfate Proteoglycans Recognized by Acidic and Basic Fibroblast Growth Factor, Biochemistry, 1994, 33:13918. |
| 2. | ↓ | Borza D-B. et al., "Domain Structure And Conformation of Histidine-Proline-Rich Glycoprotein", Biochemistry, 1996, 35; 1925-1934) |
| 3. | | Borza D-B. et al., "Acceleration of Plasminogen Activation by Tissue Plasminogen Activator On Surface-bound Histidine-Proline-Rich Glycoprotein", J. Biol. Chem., 1997, 272:5718-5726 |
| 4. | | Borza D-B. et al., "Histidine-Proline Rich Glycoprotein as a Plasma pH Sensor", J. Biol. Chem., 1998, 273:5493-5499 |
| 5. | | Simantov, R. et al., "Histidine-Rich Glycoprotein Inhibits the Antiangiogenic effect of thrombospondon-1", J. Clin. Invest. 107:45-52 (2001) |
| 6. | DB | Morgan W.T., "Histidine-Rich Glycoprotein," In: Encyclopedia of Molecular Medicine, John Wiley & Sons, vol. 3, pages 1644-1647, 2001 |

Handwritten signature: David Blumenthal

Handwritten date: 11/12/04



ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Docket No. 38342-178463

PATENT

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 1 of 1

In the application of:

Fernando DONATE et al.
U.S. Application Serial No.: 10/074,225
Filing Date: February 14, 2002

Examiner: Unassigned
Group Art Unit: 1636

RECEIVED
MAR 0 6 2003
TECH CENTER 1600/2900

For: HISTIDINE PROLINE RICH GLYCOPROTEIN
(HPTG) AS AN ANTI-ANGIOGENIC AND
ANTI-TUMOR AGENT

U.S. PATENT DOCUMENTS

Ref #	Examiner's Initials	Document Number	Date	Name	(If appropriate) Filing Date
-------	------------------------	--------------------	------	------	---------------------------------

FOREIGN PATENT DOCUMENTS

Ref #	Examiner's Initials	Document Number	Date	Country	If appropriate) Filing Date
1.	DB	WO 01/62968A2	8/30/01	WIPO	
2.	DB	WO 91/06356A1	5/16/91	WIPO	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref #	Examiner's Initials	
3.	DB	Koide et al., "Amino Acid sequence of Human Histidine-Rich Glycoprotein Derived from the Nucleotide Sequence...", April 1986, Vol. 25, No. 8, pages 2220-2225
4.	↓	Borza D-B. et al., "Domain Structure And Conformation of Histidine-Proline-Rich Glycoprotein", Biochemistry, 1996, 35; 1925-1934)
5.		Hulett et al., "Murine histidine-rich glycoprotein: Cloning, characterization and cellular origin. Immunology and Cell Biology, 2000, Vol. 78, pages 280-287
6.		Hennis et al., "Evidence for the Absence of Intron H of the Histidine-Rich Glycoprotein (HRG) Gene: Genetic Mapping and in Situ Localization of HRG to Chromosome 3q28-q29. Genomics, 1994, Vol. 19, pages 2195-197

Paul Blum

11/12/04